» Articles » PMID: 34602892

Diagnosis and Management of Refractory Gastroesophageal Reflux Disease

Overview
Specialty Gastroenterology
Date 2021 Oct 4
PMID 34602892
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

In up to half of patients with symptoms suspected to stem from gastroesophageal reflux disease (GERD), these symptoms persist despite treatment with daily proton pump inhibitor (PPI) therapy. The symptoms may be characterized as typical (eg, heartburn or regurgitation) or atypical (eg, chest pain or cough). These refractory symptoms, which are frequently encountered in clinical practice, may stem from GERD as well as non-GERD etiologies. Among those patients with objective GERD proven on esophagogastroduodenoscopy (EGD) and/ or ambulatory reflux testing, approximately one-fifth may manifest suboptimal symptom response to PPI therapy. After introducing the initial evaluation of patients with suspected GERD symptoms, this article discusses approaches to the esophageal diagnostic workup of patients with refractory symptoms in the setting of proven GERD, focusing on EGD, high-resolution manometry (HRM), and pH-impedance monitoring during treatment with PPI therapy. EGD evaluates for esophagitis, peptic stricture, and hiatal hernia, as well as eosinophilic esophagitis. HRM rules out confounding esophageal motor disorders, identifies behavioral disorders, characterizes the antireflux barrier, and assesses esophageal contractile reserve to help tailor potential antireflux interventions. pH-impedance monitoring during treatment with PPI therapy can help distinguish between PPI-refractory GERD-as evidenced by pathologic acid exposure despite PPI therapy and/or excess burden of reflux events regardless of acidity-and PPI-controlled GERD. This article also discusses potential approaches for patients with symptoms stemming from refractory GERD, encompassing lifestyle, pharmacologic, endoscopic, and surgical management options.

Citing Articles

Bolus exposure as a novel predictor of postoperative symptom resolution after laparoscopic Nissen fundoplication: a two-institutional retrospective cohort study.

Jung S, Lee I, Lee I, Lee I, Kim J, Alromi A Int J Surg. 2024; 110(12):7919-7928.

PMID: 39453844 PMC: 11634094. DOI: 10.1097/JS9.0000000000002124.


The Efficacy of Dietary Interventions in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Intervention Studies.

Lakananurak N, Pitisuttithum P, Susantitaphong P, Patcharatrakul T, Gonlachanvit S Nutrients. 2024; 16(3).

PMID: 38337748 PMC: 10857327. DOI: 10.3390/nu16030464.


Approach to Management of Refractory Gastroesophageal Reflux Disease.

Yadlapati R Gastroenterol Hepatol (N Y). 2023; 19(8):499-502.

PMID: 37772155 PMC: 10524426.


Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders.

Wong N, Reddy A, Patel A Gastroenterol Hepatol (N Y). 2023; 18(12):693-700.

PMID: 36865588 PMC: 9972603.


Laparoscopic antireflux surgery for refractory gastroesophageal reflux disease: long-term clinical outcomes.

Ugliono E, Rebecchi F, Mantova S, Osella G, Mansour A, Morino M Updates Surg. 2023; 75(4):979-986.

PMID: 36862352 PMC: 10285010. DOI: 10.1007/s13304-023-01483-x.


References
1.
Varela J, Hinojosa M, Nguyen N . Laparoscopic fundoplication compared with laparoscopic gastric bypass in morbidly obese patients with gastroesophageal reflux disease. Surg Obes Relat Dis. 2008; 5(2):139-43. DOI: 10.1016/j.soard.2008.08.021. View

2.
Lipka S, Kumar A, Richter J . No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014; 13(6):1058-67.e1. DOI: 10.1016/j.cgh.2014.10.013. View

3.
Vela M, Srinivasan R, Tutuian R, Katz P, Castell D . Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001; 120(7):1599-606. DOI: 10.1053/gast.2001.24840. View

4.
Wang Y, Pan T, Wang Q, Guo Z . Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2009; (4):CD004275. DOI: 10.1002/14651858.CD004275.pub3. View

5.
Stoikes N, Drapekin J, Kushnir V, Shaker A, Brunt L, Gyawali C . The value of multiple rapid swallows during preoperative esophageal manometry before laparoscopic antireflux surgery. Surg Endosc. 2012; 26(12):3401-7. PMC: 4098863. DOI: 10.1007/s00464-012-2350-0. View